Drug intelligence / Profile preview

R01

Development stage: Phase 1
Lead developer: Beijing Anjianxi Pharmaceutical Technology
Administration: Intramuscular

Overview

R01 is an investigational drug being evaluated for the treatment of advanced solid tumors. It is currently in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetic characteristics. The drug is also being studied in combination with first-line treatment for advanced digestive system neoplasms as a personalized mRNA vaccine (iNeo-Vac-R01).

Beyond the preview

Go deeper on R01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R01.

Explore the full profile